Johnson & Johnson (JNJ) Treasury Shares (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Treasury Shares came in at $75.9 billion in Q2 2026, up 3466.67% year-over-year from $2.1 billion in Q2 2025, and down 0.53% quarter-over-quarter from $76.3 billion in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Treasury Shares (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Treasury Shares across 18 years of filings, most recently posting $75.9 billion for Q2 2026.
- In Q2 2026, Treasury Shares rose 3466.67% year-over-year to $75.9 billion; the TTM figure through Jun 2026 stood at $75.9 billion (up 3466.67% YoY), while the FY2025 annual figure was $75.6 billion, changed 0.07% from the prior year.
- Treasury Shares came in at $75.9 billion for Q2 2026 at Johnson & Johnson, down from $76.3 billion in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $714.2 million in Q1 2025 to a low of $490.5 million in Q2 2022.
- Average Treasury Shares over 5 years is $635.8 million, with a median of $712.5 million recorded in 2024.
- Year-over-year, Treasury Shares sank 58.88% in 2024 and jumped 3482.15% in 2026.
- Over 5 years, Treasury Shares stood at $4.7 billion in 2022, then soared by 1504.71% to $75.7 billion in 2023, then increased by 0.02% to $75.7 billion in 2024, then declined by 0.07% to $75.6 billion in 2025, then gained by 0.32% to $75.9 billion in 2026.
- Per Business Quant data, the three most recent Treasury Shares figures were $75.9 billion in Q2 2026, $76.3 billion in Q1 2026, and $75.6 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 711.62 Mn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 77.11 Mn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 1.11 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | -49.00 Mn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 3.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 880.00 Mn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | - |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | - |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 711.62 Mn |
| Jun 28, 2026 | 711.62 Mn |
| Jun 28, 2026 | 75.86 Bn |
| Jun 28, 2026 | 75.86 Bn |
| Mar 29, 2026 | 76.26 Bn |
| Mar 29, 2026 | 713.26 Mn |
| Mar 29, 2026 | 76.26 Bn |
| Mar 29, 2026 | 713.26 Mn |
| Dec 28, 2025 | 75.62 Bn |
| Dec 28, 2025 | 711.90 Mn |
| Dec 28, 2025 | 75.62 Bn |
| Dec 28, 2025 | 711.90 Mn |
| Sep 28, 2025 | 75.89 Bn |
| Sep 28, 2025 | 75.89 Bn |
| Sep 28, 2025 | 713.65 Mn |
| Sep 28, 2025 | 713.65 Mn |
| Jun 29, 2025 | 713.06 Mn |
| Jun 29, 2025 | 713.06 Mn |
| Jun 29, 2025 | 2.13 Bn |
| Jun 29, 2025 | 2.13 Bn |